Market Overview

UPDATE: Piper Jaffray Upgrades Alnylam Pharmaceuticals to Overweight; Overhang Removed

Share:
Related ALNY
4 Biotechs Piper Jaffray Is Buying On The Pullback
Here's One Biotech Stock JMP Analysts Are Very Bullish On
Premarket Biotech Digest: CLL Treatment, Gilead CEO Sells, Acelity IPO (Seeking Alpha)

Piper Jaffray raised its rating on Alnylam Pharmaceuticals (NASDAQ: ALNY) from Neutral to Overweight and increased its price target from $19 to $25.

Piper Jaffray noted, "With the Tekmira litigation behind them, Alnylam can now focus on RNAi clinical progress and partnerships in 2013. Specifically, we look forward to Phase II ALN-TTR02 data this summer to prepare the company for pivotal studies by year-end. We also expect Alnylam to file INDs on sub-cutaneous formulations of ALN-TTR02 and ALN-AT3, an innovative hemophilia therapy. We also look for Alnylam to continue to partner its RNAi therapeutic pipeline, most importantly ALN-PCS to lower cholesterol."

Alnylam Pharmaceuticals closed at $17.99 on Tuesday.

Latest Ratings for ALNY

DateFirmActionFromTo
Aug 2015FBR CapitalInitiates Coverage onOutperform
Aug 2015JP MorganDowngradesOverweightNeutral
Aug 2015JP MorganMaintainsNeutral

View More Analyst Ratings for ALNY
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (ALNY)

View Comments and Join the Discussion!

Get Benzinga's Newsletters